HER2 FPBMC in Patients With Metastatic Breast and Prostate Cancer (AM006)

The purpose of this study is to understand the safety and estimate the efficacy of anti-CD3 x anti-HER2 bispecific antibody (HER2Bi) armed fresh peripheral blood mononuclear cells (HER2 FPBMC) for patients with metastatic breast or prostate cancer. Participants receive 5 weekly doses of CD33 FPBMC by intravenous infusion followed by 4 infusions every other week.

Trial Details

NCT ID
NCT07441889
Phase
PHASE1 / PHASE2
Sponsor
University of Virginia
Status
RECRUITING
Cancer Type
Prostate Cancer
Interventions
  • HER2 FPBMC
Locations (sample)
  • Charlottesville, Virginia, United States|38.02931,-78.47668

Key Eligibility Criteria

  • Provision of signed and dated informed consent form
  • Stated willingness to comply with all study procedures and availability for the duration of the study
  • Age ≥ 18 years at the time of signing informed consent
  • Expected survival ≥ 3 months in the judgment of the investigator

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →